These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 17690571)

  • 21. Early changes in adipokine levels and baseline limb fat may predict HIV lipoatrophy over 2 years following initiation of antiretroviral therapy.
    Calmy A; Carey D; Mallon PW; Wand H; Law M; Cooper DA; Carr A; ;
    HIV Med; 2008 Feb; 9(2):101-10. PubMed ID: 18257772
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In utero nucleoside reverse transcriptase inhibitor exposure and signs of possible mitochondrial dysfunction in HIV-uninfected children.
    Brogly SB; Ylitalo N; Mofenson LM; Oleske J; Van Dyke R; Crain MJ; Abzug MJ; Brady M; Jean-Philippe P; Hughes MD; Seage GR
    AIDS; 2007 May; 21(8):929-38. PubMed ID: 17457086
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anthropometrics and examiner-reported body habitus abnormalities in the multicenter AIDS cohort study.
    Palella FJ; Cole SR; Chmiel JS; Riddler SA; Visscher B; Dobs A; Williams C
    Clin Infect Dis; 2004 Mar; 38(6):903-7. PubMed ID: 14999638
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of PI and NNRTI HAART-based therapy on oral lesions of Brazilian HIV-infected patients.
    Ortega KL; Vale DA; Magalhães MH
    J Oral Pathol Med; 2009 Jul; 38(6):489-94. PubMed ID: 19453845
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influence of antiretroviral therapy on oxidative stress and cardiovascular risk: a prospective cross-sectional study in HIV-infected patients.
    Masiá M; Padilla S; Bernal E; Almenar MV; Molina J; Hernández I; Graells ML; Gutiérrez F
    Clin Ther; 2007 Jul; 29(7):1448-55. PubMed ID: 17825696
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Effect of antiretroviral therapy on carotid intima-media thickness in HIV-infected patients].
    Ferraro S; Paolillo S; Gargiulo M; Costanzo P; Maggi P; Chirianni A; Chiariello M; Filardi PP
    G Ital Cardiol (Rome); 2009 Sep; 10(9):596-601. PubMed ID: 19891251
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Distinct mechanisms for mitochondrial DNA loss in T and B lymphocytes from HIV-infected patients exposed to nucleoside reverse-transcriptase inhibitors and those naive to antiretroviral treatment.
    Maagaard A; Holberg-Petersen M; Løvgården G; Holm M; Pettersen FO; Kvale D
    J Infect Dis; 2008 Nov; 198(10):1474-81. PubMed ID: 18851688
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Second-line antiretroviral therapy in resource-limited settings: the experience of Médecins Sans Frontières.
    Pujades-Rodríguez M; O'Brien D; Humblet P; Calmy A
    AIDS; 2008 Jul; 22(11):1305-12. PubMed ID: 18580610
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of nucleoside reverse transcriptase inhibitors in the fat redistribution syndrome.
    Nolan D; Mallal S
    J HIV Ther; 2004 May; 9(2):34-40. PubMed ID: 15238874
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the Multicenter AIDS Cohort Study.
    Brown TT; Li X; Cole SR; Kingsley LA; Palella FJ; Riddler SA; Chmiel JS; Visscher BR; Margolick JB; Dobs AS
    AIDS; 2005 Sep; 19(13):1375-83. PubMed ID: 16103768
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Two-year outcomes of children on non-nucleoside reverse transcriptase inhibitor and protease inhibitor regimens in a South African pediatric antiretroviral program.
    Jaspan HB; Berrisford AE; Boulle AM
    Pediatr Infect Dis J; 2008 Nov; 27(11):993-8. PubMed ID: 18818556
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of the substitution of one nucleoside analogue by one non-nucleoside reverse transcriptase inhibitor over mitochondrial DNA levels.
    De Felipe B; Blanco A; Soriano-Sarabia N; Muñoz-Fernández MA; Genebat M; Vallejo A; Leal M
    Infection; 2008 Jun; 36(3):266-70. PubMed ID: 18463785
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Detection of lipoatrophy in human immunodeficiency virus-1-infected children treated with highly active antiretroviral therapy.
    Hartman K; Verweel G; de Groot R; Hartwig NG
    Pediatr Infect Dis J; 2006 May; 25(5):427-31. PubMed ID: 16645507
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Successful simplification of protease inhibitor-based HAART with triple nucleoside regimens in children vertically infected with HIV.
    Palma P; Romiti ML; Cancrini C; Pensieroso S; Montesano C; Santucci MB; Bernardi S; Martino AM; Rossi P; Castelli-Gattinara G
    AIDS; 2007 Nov; 21(18):2465-72. PubMed ID: 18025883
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A prospective study of waist circumference and body mass index in relation to colorectal cancer incidence.
    Wang Y; Jacobs EJ; Patel AV; Rodríguez C; McCullough ML; Thun MJ; Calle EE
    Cancer Causes Control; 2008 Sep; 19(7):783-92. PubMed ID: 18322811
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Growth hormone secretion among HIV infected patients: effects of gender, race and fat distribution.
    Koutkia P; Eaton K; You SM; Breu J; Grinspoon S
    AIDS; 2006 Apr; 20(6):855-62. PubMed ID: 16549969
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Body composition and pulmonary function in the elderly: a 7-year longitudinal study.
    Rossi A; Fantin F; Di Francesco V; Guariento S; Giuliano K; Fontana G; Micciolo R; Solerte SB; Bosello O; Zamboni M
    Int J Obes (Lond); 2008 Sep; 32(9):1423-30. PubMed ID: 18645577
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trial.
    Soulié C; Assoumou L; Ghosn J; Duvivier C; Peytavin G; Ait-Arkoub Z; Molina JM; Costagliola D; Katlama C; Calvez V; Marcelin AG
    AIDS; 2009 Jul; 23(12):1605-8. PubMed ID: 19487903
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Overweight HIV patients with abdominal fat distribution treated with protease inhibitors are at high risk for abnormalities in glucose metabolism - a reason for glycemic control.
    Blass SC; Ellinger S; Vogel M; Ingiliz P; Spengler U; Stehle P; von Ruecker A; Rockstroh JK
    Eur J Med Res; 2008 May; 13(5):209-14. PubMed ID: 18559303
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Boosted protease inhibitor-based or nonnucleoside reverse transcriptase-based HAART: is there a best choice for antiretroviral-naive HIV-1 infected patients?
    Cuzin L; Allavena C; Morlat P; Dellamonica P
    AIDS Rev; 2008; 10(4):205-11. PubMed ID: 19092976
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.